title: Myocardial ultrasonic tissue characterization in pediatric and adult patients with hypertrophic cardiomyopathy.
abstract: BACKGROUND
  Hypertrophic cardiomyopathy (HCM) has different clinical and prognostic aspects in young than in adult patients. This study was undertaken to determine whether these reported differences are reflected by changes in ultrasonic backscatter parameters and whether oral treatment with verapamil modifies backscatter variables in children with HCM.
  
  
  RESULTS
  Sixty-eight subjects underwent backscatter analysis to assess the ultrasonic myocardial reflectivity and the amplitude of the cardiac cycle-dependent variation of the backscatter power curve. Subjects were divided into four groups: 10 HCM and 23 normal subjects < 10 years old and 17 HCM and 18 normal adults. Myocardial reflectivity and amplitude of the cyclic variation were assessed in the septum and in the posterior wall of all subjects. The children with HCM were restudied after long-term oral administration of verapamil. Both children and adult patients, compared with the normal control groups, showed a significant reduction in the amplitude of the cyclic variation both in the septum and in the posterior wall. In contrast, myocardial reflectivity, although significantly increased in adult HCM patients, was unchanged in the young HCM group. Verapamil administration did not significantly alter the results in the children with HCM.
  
  
  CONCLUSIONS
  These data demonstrate that in young HCM patients, the ultrasonic myocardial reflectivity is normal, in contrast to the significant increase observed in adult patients affected by the same disease. This observation is in accord with the different clinical manifestations reported in young HCM patients and indicates an age-dependent difference in the echogenic structure of the hypertrophied myocardium in HCM.
authors.affiliation: Facoltà di Medicina Federico II, Cattedra di Geriatria, Naples, Italy.
authors.forename: D F
authors.initials: DF
authors.lastname: Vitale
authors.forename: R O
authors.initials: RO
authors.lastname: Bonow
authors.forename: R
authors.initials: R
authors.lastname: Calabrò
authors.forename: M
authors.initials: M
authors.lastname: De Cristofaro
authors.forename: G
authors.initials: G
authors.lastname: Pacileo
authors.forename: P
authors.initials: P
authors.lastname: Caso
authors.forename: G
authors.initials: G
authors.lastname: Gerundo
authors.forename: C
authors.initials: C
authors.lastname: Bordini
authors.forename: M A
authors.initials: MA
authors.lastname: Losi
authors.forename: C
authors.initials: C
authors.lastname: Rengo
authors.forename: F
authors.initials: F
authors.lastname: Rengo
mesh_terms: D000328:Adult; D000375:Aging / Q000502:physiology*; D002312:Cardiomyopathy, Hypertrophic / Q000000981:diagnostic imaging* / Q000188:drug therapy; D002648:Child; D002675:Child, Preschool; D004452:Echocardiography; D006801:Humans; D008875:Middle Aged; D014700:Verapamil / Q000627:therapeutic use
chemical_list: D014700:Verapamil